CancerDrs

Prostate Cancer clinical trials in South Dakota

5 actively recruiting prostate cancer trials at 5 sites across South Dakota.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Industry

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in South Dakota:
  • Avera Cancer Institute - Aberdeen (Site 0123) — Aberdeen, South Dakota
  • Avera Cancer Institute - Mitchell (Site 0121) — Mitchell, South Dakota
  • Avera Cancer Institute - Pierre ( Site 0118) — Pierre, South Dakota
  • Avera Cancer Institute- Research ( Site 0094) — Sioux Falls, South Dakota
  • Avera Cancer Institute - Yankton ( Site 0117) — Yankton, South Dakota
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in South Dakota:
  • Avera Medical Group — Sioux Falls, South Dakota
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in South Dakota:
  • Avera Cancer Institute - Pierre ( Site 0118) — Pierre, South Dakota
  • Avera Cancer Institute- Research ( Site 0094) — Sioux Falls, South Dakota
  • Avera Cancer Institute - Yankton ( Site 0117) — Yankton, South Dakota
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amen…

Sponsor: Amgen
NCT ID: NCT04221542
Sites in South Dakota:
  • Sanford Oncology Clinic and Pharmacy — Sioux Falls, South Dakota
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in South Dakota:
  • Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
  • Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07